Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson Sells 15,000 Shares

Apogee Therapeutics, Inc. (NASDAQ:APGE) CEO Michael Thomas Henderson sold 15,000 shares of the stock in a transaction that occurred on Wednesday, January 8th. The stock was sold at an average price of $48.85, for a total value of $732,750.00. Following the transaction, the chief executive officer now directly owns 1,309,487 shares of the company’s stock, valued at approximately $63,968,439.95. This trade represents a 1.13 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Michael Thomas Henderson also recently made the following trade(s):

• On Wednesday, December 4th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The stock was sold at an average price of $46.58, for a total value of $698,700.00.
• On Wednesday, November 6th, Michael Thomas Henderson sold 15,000 shares of Apogee Therapeutics stock. The shares were sold at an average price of $59.22, for a total value of $888,300.00.

Apogee Therapeutics Price Performance

APGE stock opened at $41.05 on Friday. The company’s 50 day simple moving average is $48.70 and its 200-day simple moving average is $48.90. Apogee Therapeutics, Inc. has a 12 month low of $30.84 and a 12 month high of $72.29. The firm has a market capitalization of $1.85 billion, a PE ratio of -16.96 and a beta of 2.26.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently issued reports on the stock. Wedbush increased their price target on shares of Apogee Therapeutics from $87.00 to $90.00 and gave the company an “outperform” rating in a report on Monday, December 2nd. Canaccord Genuity Group began coverage on shares of Apogee Therapeutics in a research report on Monday, November 25th. They set a “buy” rating and a $89.00 price target for the company. Canaccord Genuity Group assumed coverage on Apogee Therapeutics in a report on Monday, November 25th. They issued a “buy” rating and a $89.00 price target on the stock. Finally, Guggenheim reaffirmed a “buy” rating on shares of Apogee Therapeutics in a report on Thursday, December 12th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat, Apogee Therapeutics currently has an average rating of “Buy” and an average price target of $89.71.

Institutional Investors Weigh In On Apogee Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of APGE. Zurcher Kantonalbank Zurich Cantonalbank acquired a new position in shares of Apogee Therapeutics in the third quarter worth $71,000. Mirae Asset Global Investments Co. Ltd. increased its position in Apogee Therapeutics by 21.2% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,628 shares of the company’s stock worth $94,000 after purchasing an additional 285 shares in the last quarter. Wexford Capital LP acquired a new position in Apogee Therapeutics in the 3rd quarter valued at about $230,000. Arizona State Retirement System lifted its holdings in Apogee Therapeutics by 4.5% in the 2nd quarter. Arizona State Retirement System now owns 5,993 shares of the company’s stock valued at $236,000 after purchasing an additional 258 shares in the last quarter. Finally, Principal Financial Group Inc. boosted its stake in shares of Apogee Therapeutics by 26.3% during the 2nd quarter. Principal Financial Group Inc. now owns 6,442 shares of the company’s stock worth $253,000 after purchasing an additional 1,340 shares during the last quarter. Hedge funds and other institutional investors own 79.04% of the company’s stock.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.